

## Publications Relating to Effects of Artemisinin and its Analogs on Cancer (9/24/10):

1. Al-Oqail, M.M., Galal, A.M., Ahmad, M.S., Al-Fishawi, A.M. & El-Feraly, F.S. New bioactive azaartemisinin derivatives. *Molecules* **8**, 901-909 (2003).
2. Anfosso, L., Efferth, T., Albini, A. & Pfeffer, U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. *Pharmacogenomics Journal* **6**, 269-278 (2006).
3. Beekman, A.C. et al. Artemisinin-derived sesquiterpene lactones as potential antitumor compounds. Cytotoxic action against bone marrow and tumor cells. *Planta Medica* **64**, 615-619 (1998).
4. Beekman, A.C., Woerdenbag, H.J., Kampinga, H.H. & Konings, A.W.T. Cytotoxicity of artemisinin, a dimer of dihydroartemisinin, artemisitene and eupatoriopicrin as evaluated by the MTT and clonogenic assay. *Phytotherapy Research* **10**, 140-144 (1996).
5. Beekman AC et al. Stereochemistry-dependent cytotoxicity of some artemisinin derivatives. *J Nat Prod* **60**, 325-330 (1997).
6. Beekman, A.C. et al. Stability of artemisinin in aqueous environments: impact on its cytotoxic action to Ehrlich ascites tumour cells. *The Journal of Pharmacy and Pharmacology* **49**, 1254-1258 (1997).
7. Berger, T.G. et al. Artesunate in the treatment of metastatic uveal melanoma - first experiences. *Oncology Reports* **14**, 1599-1603 (2005).
8. Buommino E, Baroni A, Canozo N, Petrazzuolo M, Nicoletti R, Vozza A, Tufano MA. Artemisinin reduces human melanoma cell migration by down-regulating alphaVbeta3 integrin and reducing metalloproteinase 2 production. *Invest New Drugs* **27**, 412-418 (2009)
9. Cai HH, Cai J, Yang PH. Electrochemical activity of holotransferrin and its electrocatalysis-mediated process of artemisinin. *Bioorg Med Chem Lett.* **19**, 863-866 (2009)
10. Cao, P. & Wang, Z. Antitumor activities of artemisinin and its derivatives. *Zhongliu Fangzhi Zazhi* **11**, 666-668 (2004).
11. Chadwick, J., Mercer, A.E., Park, B.K., Cosstick, R. & O'Neill, P.M. Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against *P. falciparum* malaria parasites and HL-60 cancer cells. *Bioorganic & Medicinal Chemistry* **17**, 1325-1338 (2009).
12. Chadwick J, Jones M, Mercer AE, Stocks PA, Ward SA, Park BK, O'Neill PM. Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in *Plasmodium falciparum* and HL-60 cancer cell lines. *Bioorg Med Chem.* **18**, 2586-597 (2010)
13. Chen, H., Sun, B., Pan, S., Jiang, H. & Sun, X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. *Anti-Cancer Drugs* **20**, 131-140 (2009).
14. Chen, H. & Zhou, H. Inhibitory effects of artesunate on angiogenesis. *Yaoxue Xuebao* **39**, 29-33 (2004).
15. Chen H, Sun B, Pan SH, Li J, Xue DB, Meng QH, Jiang HC. Study on anticancer effect of dihydroartemisinin on pancreatic cancer. *Zhonghua Wai Ke Za Zhi.* **47(13)**:1002-1005 (2009).
16. Chen H, Sun B, Wang S, Pan S, Gao Y, Bai X, Xue D Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. *J Cancer Res Clin Oncol.* **136**, 897-903 (2010)

17. Chen, H.-H., Zhou, H.-J. & Fang, X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. *Pharmacological Research* **48**, 231-236 (2003).
18. Chen, H.-H., Zhou, H.-J., Wang, W.Q. & Wu, G.D. Antimalarial dihydroartemisinin also inhibits angiogenesis. *Cancer Chemther Pharmacol* **53**:423-431 (2004)
19. Chen, H.-H., Zhou, H.-J., Wu, G.-D. & Lou, X.-E. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. *Pharmacology* **71**, 1-9 (2004).
20. Chen T et al. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. *J Cell Mol Med*. 2008 May 2 [Epub ahead of print].
21. Chen, Y., Lin, X., Park, H. & Greever, R. Study of artemisinin nanocapsules as anticancer drug delivery systems. *Nanomedicine*. 2009 Jan 18. [Epub ahead of print]
22. Cho, S., Oh, S., Um, Y., Jung, J.H., Ham, J., Shin, W.S. & Lee, S. Synthesis of 10-substituted triazolyl artemisinins possessing anticancer activity via Huisgen 1,3-dipolar cycloaddition. *Bioorg Med Chem Lett* **19**, 382-385 (2009).
23. Chung, S.Y. et al. Effect of natural compounds on P-glycoprotein activity in human uterine sarcoma cells. *Yakche Hakhoechi* **35**, 249-254 (2005).
24. Chung, S.Y. et al. Inhibition of P-glycoprotein by natural products in human breast cancer cells. *Archives of Pharmacol Research* **28**, 823-828 (2005).
25. Cui, C. et al. Influence of artesunate and oxymatrine on immunosuppressive effect of mouse colon-rectal carcinoma cell line. *Xiandai Mianyixue* **26**, 152-156 (2006).
26. D'Alessandro S., Gelati M., Basilico N., Parati E.A., Haynes R.K & Taramelli D. Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: implications for embryotoxicity. *Toxicology* **241**, 66-74 (2007).
27. Dell'Eva, R. et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. *Biochemical Pharmacology* **68**, 2359-2366 (2004).
28. Deng, D.A., Xu, C.H. & Cai, J.C. Derivatives of arteannuin B with antileukemia activity. *Acta Pharmaceutica Sinica* **27**(4): 317-320 (1992)
29. Deng, X.-R., Yu, H.-P., Wang, K.-Q. & Li, X.-M. Inhibitory effect of artemisinin on hepatoma H22 cells. *Shiyong Linchuang Yixue* **8**, 1-3, 7 (2007).
30. Disbrow, G.L. et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. *Cancer Research* **65**, 10854-10861 (2005).
31. Du, J.-H., Ma, Z.-J., Li, J.-X. & Zhang, H.-D. An oncosis-like cell death of pancreatic cancer Panc-1 cells induced by artesunate is related to generation of reactive oxygen species. *Zhongguo Aizheng Zazhi* **18**, 410-414 (2008).
32. Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. *Cancer Chemother Pharmacol*. **65**(5): 895-902, 2010.
33. Efferth, T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. *Drug Resistance Updates* **8**, 85-97 (2005).
34. Efferth, T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. *Current Drug Targets* **7**, 407-421 (2006).
35. Efferth, T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. *Planta Medica* **73**, 299-309 (2007).
36. Efferth, T. et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous

- iron. *Free Radical Biology & Medicine* **37**, 998-1009 (2004).
37. Efferth, T., Briehl, M.M. & Tome, M.E. Role of antioxidant genes for the activity of artesunate against tumor cells. *International Journal of Oncology* **23**, 1231-1235 (2003).
  38. Efferth, T. et al. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. *Blood cells, Molecules & Diseases* **28**, 160-168 (2002).
  39. Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H. & Chitambar, C.R. The anti-malarial artesunate is also active against cancer. *International Journal of Oncology* **18**, 767-773 (2001).
  40. Efferth, T., Giaisi, M., Merling, A., Krammer Peter, H. & Li-Weber, M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. *PLoS ONE* **2**, e693 (2007).
  41. Efferth, T. et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. *Clinical Cancer Research* **14**, 2405-2412 (2008).
  42. Efferth, T., Li, P.C.H., Konkimalla, V.S.B. & Kaina, B. From traditional Chinese medicine to traditional cancer therapy. *Trends in Molecular Medicine* **13**, 353-361 (2007).
  43. Efferth, T. & Oesch, F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. *Biochemical Pharmacology* **68**, 3-10 (2004).
  44. Efferth, T., Olbrich, A. & Bauer, R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. *Biochemical Pharmacology* **64**, 617-623 (2002).
  45. Efferth, T., Ramirez, T., Gebhart, E. & Halatsch, M.-E. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. *Biochemical Pharmacology* **67**, 1689-1700 (2004).
  46. Efferth, T. et al. Molecular modes of action of artesunate in tumor cell lines. *Molecular Pharmacology* **64**, 382-394 (2003).
  47. Efferth, T. & Volm, M. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. *In Vivo* **19**, 225-232 (2005).
  48. Fan, Y., Zheng, S. & Zhao, G. Effects of artesunate on anoikis resistance in human breast cancer cell MCF-7. *Zhongguo Bingli Shengli Zazhi* **22**, 748-751 (2006).
  49. Ferreira JF, Luthria DL, Sasaki T, Heyerick A. Flavonoids from *Artemisia annua* L. as Antioxidants and Their Potential Synergism with Artemisinin against Malaria and Cancer. *Molecules*. 15(5):3135-3170 (2010).
  50. Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. *Expert Rev Mol Med*. 11:e32 (2009).
  51. Fujita, T. et al. Human fortilin is a molecular target of dihydroartemisinin. *FEBS Letters* **582**, 1055-1060 (2008).
  52. Galal A.M. et al. Deoxyartemisinin derivatives from photooxygenation of anhydrodeoxydihydroartemisinin and their cytotoxic evaluation. *Journal of Natural Products* **65**, 184-188 (2002).
  53. Galal, A.M. et al. Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. *Bioorganic & Medicinal Chemistry* **17**, 741-751 (2009).
  54. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made

- sesquiterpene lactones reach cancer clinical trials? *Drug Discov Today*. 2010 Jun 8. [Epub ahead of print]
55. Handrick R, Ontikatze T, Bauer KD, Freier F, Rübél A, Dürig J, Belka C, Jendrosseck V. Dihydroartemisinin Induces Apoptosis by a Bak-dependent Intrinsic Pathway. *Mol Cancer Ther*. 2010 Jul 27. [Epub ahead of print]
  56. He RR, Zhou HJ. Progress in research on the anti-tumor effect of artesunate. *Chin J Integr Med*. 14(4):312-316 (2008).
  57. He Y, Fan J, Lin H, Yang X, Ye Y, Liang L, Zhan Z, Dong X, Sun L, Xu H. The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte. *Rheumatol Int*. 2009 Oct 27. [Epub ahead of print]
  58. Hosoya, K. et al. Biological activity of dihydroartemisinin in canine osteosarcoma cells lines. *American Journal of Veterinary Research* **69**, 519-526 (2008).
  59. Hou, J., Wang, D., Zhang, R. & Wang, H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. *Clinical Cancer Research* **14**, 5519-5530 (2008).
  60. Hu YQ et al. Apoptosis in human hepatoma cell line SMMC-7721 induced by water-soluble macromolecular components of *Artemisia capillaris* Thunberg. *Japanese Journal of Cancer Research* **91**, 113-117 (2000).
  61. Huan-Huan C et al. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. *Cancer Letters* **211**,163-173 (2004).
  62. Huang, X.-F., Yuan, D., Zhang, C.-C. & Zhang, X.-P. Artesunate induces human prostate cancer cell line PC-3 differentiation and cell cycle arrest. *Zhongxiyi Jiehe Xuebao* **6**, 591-594 (2008).
  63. Huang, X.-J. et al. Dihydroartemisinin Potentiates the Cytotoxic Effect of Temozolomide in Rat C6 Glioma Cells. *Pharmacology* **82**, 1-9 (2008).
  64. Huang, X.-J., Ma, Z.-Q., Zhang, W.-P., Lu, Y.-B. & Wei, E.-Q. Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. *Journal of Pharmacy and Pharmacology* **59**, 849-856 (2007).
  65. Hwang YP, Yun HJ, Kim HG, Han EH, Lee GW, Jeong HG. Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. *Biochem Pharmacol*. 2010 Feb 9. [Epub ahead of print]
  66. Jansen, F.H. & Soomro, S.A. Chemical instability determines the biological action of the artemisinins. *Current Medicinal Chemistry* **14**, 3243-3259 (2007).
  67. Jeyadevan, J.P. et al. Antimalarial and Antitumor Evaluation of Novel C-10 Non-Acetal Dimers of beta -(2-Hydroxyethyl) deoxyartemisinin. *Journal of Medicinal Chemistry* **47**, 1290-1298 (2004).
  68. Jiao, Y. et al. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. *Acta Pharmacologica Sinica* **28**, 1045-1056 (2007).
  69. Jones, M., Mercer, A.E., Stocks, P.A., La Pensée, L.J., Cosstick, R., Park, B.K., Kennedy, M.E., Piantanida, I., Ward, S.A., Davies, J., Bray, P.G., Rawe, S.L., Baird, J., Charidza, T., Janneh, O., O'Neill, P.M. Antitumour and antimalarial activity of artemisinin-acridine hybrids. *Bioorganic & Medicinal Chemistry Letters* **19**:2033-2037 (2009).
  70. Jung, M., Tak, J., Chung, W.-Y. & Park, K.-K. Antiangiogenic activity of deoxyartemisinin

- derivatives on chorioallantoic membrane. *Bioorganic & Medicinal Chemistry Letters* **16**, 1227-1230 (2006).
71. Kelter, G. et al. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. *PLoS One* **2**, (2007).
  72. Kim, S.H., Chun, S.-Y. & Kim, T.S. Interferon-alpha enhances artemisinin-induced differentiation of HL-60 leukemia cells via a PKCalpha /ERK pathway. *European Journal of Pharmacology* **587**, 65-72 (2008).
  73. Kim S.H. et al. Differential involvement of protein kinase C in human promyelocytic leukemia cell differentiation enhanced by artemisinin. *European Journal of Pharmacology* **482**, 67-76 (2003).
  74. Kim, S.J. et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. *Journal of Cancer Research and Clinical Oncology* **132**, 129-135 (2006).
  75. Konkimalla, V.B. et al. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. *Nitric Oxide* **19**, 184-191 (2008).
  76. Konkimalla, V.B., McCubrey James, A. & Efferth, T. The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. *Current Cancer Drug Targets* **9**, 72-80 (2009).
  77. Krishna, S., Bustamante, L., Haynes, R.K. & Staines, H.M. Artemisinins: their growing importance in medicine. *Trends in Pharmacological Sciences* **29**, 520-527 (2008).
  78. Lai, H. & Singh, N.P. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. *Cancer Letters* **91**, 41-46 (1995).
  79. Lai, H., Sasaki, T. & Singh, N.P. Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. *Expert Opinion on Therapeutic Targets* **9**, 995-1007 (2005).
  80. Lai, H., Sasaki, T., Singh, N.P. & Messay, A. Effects of artemisinin-tagged holotransferrin on cancer cells. *Life Sciences* **76**, 1267-1279 (2005).
  81. Lai, H. & Singh, N.P. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. *Cancer Letters* **231**, 43-48 (2006).
  82. Lai, H., Nakase I., Lacoste E., Singh N.P. & Sasaki, T. Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. *Anticancer Research* **29**, 3807-3810 (2009)
  83. Langroudi L, Hassan ZM, Ebtakar M, Mahdavi M, Pakravan N, Noori S. A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. *Int Immunopharmacol*. 2010 Jun 30. [Epub ahead of print]
  84. Lee, C.-H. et al. NMR studies on novel antitumor drug candidates, deoxoartemisinin and carboxypropyldeoxoartemisinin. *Biochemical and Biophysical Research Communications* **274**, 359-369 (2000).
  85. Lee J. et al. Dihydroartemisinin down-regulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. *Cancer Chemother Pharmacol* **57**, 213-220 (2006).
  86. Li J and Zhou HJ. Dihydroartemisinin inhibits the expression of vascular endothelial growth factor in K562 cells. *Yao Xue Xue Bao* **240**, 1041-1045 (2005).
  87. Li, L.-N. et al. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta -catenin pathway. *International Journal of Cancer* **121**, 1360-1365

- (2007).
88. Li, L.-N. et al. Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. *European Journal of Pharmacology* **588**, 1-8 (2008).
  89. Li, P., Wang, G. & Zhang, Y. Advances in pharmacological action of artesunate. *Jishengchongbing Yu Ganranxingjibing* **6**, 109-111 (2008).
  90. Li, P.C.H. et al. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. *Cancer Research* **68**, 4347-4351 (2008).
  91. Li, S., Pan, L. & Xue, F. Effects of artesunate on myeloma cell line SP2/0 and its mechanism. *Zhonghua Zhongliu Zazhi* **30**, 16-20 (2008).
  92. Li, S.-H. & Pan, L. Research advances in antitumor mechanism of artemisinin and its derivatives. *Zhongchengyao* **29**, 561-562 (2007).
  93. Li, S.-H., Pan, L. & Xue, F. Strong suppression of SP2/0 myeloma cell proliferation and enhanced apoptosis by artesunate. *Zhongchengyao* **29**, 434-435 (2007).
  94. Li W et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. *PLoS Genet* **1(3)**, e36 (2005).
  95. Li, X., Ling, V. & Li Paul, C.H. Same-single-cell analysis for the study of drug efflux modulation of multidrug resistant cells using a microfluidic chip. *Analytical chemistry* **80**, 4095-4102 (2008).
  96. Li Y et al. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. *Bioorg Med Chem Lett* **11**, 5-8 (2001).
  97. Lin, F., Qian, Z., Xue, H., Ding, J. & Lin, L. Comparison of inhibitory effects between artemisinin and artemisunate on proliferation of MCF-7 cells in vitro. *Zhongcaoyao* **34**, 347-349 (2003).
  98. Liu, L., Wang, J., Liu, J., Guo, J. & Zuo, L. Inhibitory effect of artesunate on human esophageal squamous carcinoma and its related mechanism. *Zhongguo Yike Daxue Xuebao* **37**, 529-531 (2008).
  99. Liu, X. et al. Artesunate reverses immunosuppression of 1929 tumor cells. *Zhongguo Mianyixue Zazhi* **23**, 985-988 (2007).
  100. Liu, Y., Wong, V.K.-W., Ko, B.C.-B., Wong, M.-K. & Che, C.-M. Synthesis and cytotoxicity studies of artemisinin derivatives containing lipophilic alkyl carbon chains. *Organic Letters* **7**, 1561-1564 (2005).
  101. Liu Y, Lok CN, Ko BC, Shum TY, Wong MK, Che CM. Subcellular localization of a fluorescent artemisinin derivative to endoplasmic reticulum. *Org Lett.* 12(7):1420-1423 (2010)
  102. Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. *Cancer Lett.* 2010 Aug 2. [Epub ahead of print]
  103. Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. *Cancer Biol Ther.* **7**, 1017-1023 (2008)
  104. Lu, J.J., Meng, L.H., Shankavaram, U.T., Zhu, C.H., Tong, L.J., Chen, G., Lin, L.P., Weinstein, J.N., & Ding, J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. *Biochem Pharmacol.* 2010 Mar 2. [Epub ahead of print]
  105. Lu JJ, Chen SM, Zhang XW, Ding J, Meng LH. The anti-cancer activity of

- dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. *Invest New Drugs*. 2010 Jul 7. [Epub ahead of print]
106. Lu, Y.Y., Chen, T.S., Qu, J.L., Pan, W.L., Sun, L. & Wei, X.B. Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. *J Biomed Sci*. 16(1):16 (2009).
  107. Ma J, Chen L, Liao R, Xu S, Li M, Xu D, Li W. Effects of artemether and dihydroarteannuin on mouse model of scleroderma. *Zhongguo Zhong Yao Za Zhi*. **34**, 204-207 (2009).
  108. McCarty, M.F. Turning an 'Achilles' Heel' into an asset - activation of HIF-1-alpha during angiostatic therapy will increase tumor sensitivity to iron-catalyzed oxidative damage. *Medical Hypotheses* **61**, 509-511 (2003).
  109. Meng, Y., Li, Y., Liu, B. & Wu, J. Inhibitory effect of pair of hydrogen artemisinin on HeP-2 cells of throat cancer. *Disi Junyi Daxue Xuebao* **25**, 2270-2272 (2004).
  110. Mercer, A.E. et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. *Journal of Biological Chemistry* **282**, 9372-9382 (2007).
  111. Michaelis M, Kleinschmidt MC, Barth S, Rothweiler F, Geiler J, Breitling R, Mayer B, Deubzer H, Witt O, Kreuter J, Doerr HW, Cinatl J, Cinatl J Jr. Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. *Biochem Pharmacol*. 2009 Aug 18. [Epub ahead of print]
  112. Moore, J.C., Lai, H., Li, J.R., Ren, R.L., McDougall, J.A., Singh, N.P. & Chou, C.K. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. *Cancer Letters* **98**, 83-87 (1995).
  113. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. *Anticancer Drugs*. 2010 Feb 2. [Epub ahead of print]
  114. Mu, D. et al. Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. *Methods and Findings in Experimental and Clinical Pharmacology* **29**, 33-38 (2007).
  115. Mu, D. et al. The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. *Cancer Chemotherapy and Pharmacology* **61**, 639-645 (2008).
  116. Mukanganyama, S., Widersten, M., Naik, Y.S., Mannervik, B. & Hasler, J.A. Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. *International Journal of Cancer* **97**, 700-705 (2002).
  117. Nakase, I., Gallis, B., Takatani-Nakase, T., Oh, S., Lacoste E., Singh, N.P., Goodlet, D.R., Tanaka, S., Futaki, S., Lai, H. & Sasaki, T. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. *Cancer Letters* **274**, 290-298 (2009).
  118. Nakase, I., Lai, H., Singh, N.P., Sasaki, T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. *International Journal of Pharmaceutics* **354**, 28-33 (2008).
  119. Nam, W. et al. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. *Head & Neck* **29**, 335-340 (2007).
  120. Noori S, Taghikhani M, Hassan ZM, Allameh A, Mostafaei A. Tehranolide could shift the immune response towards Th1 and modulate the intra-tumor infiltrated T regulatory cells. *Iran J Immunol*. 6(4):216-224, 2009.

121. Noori S, Taghikhani M, Hassan ZM, Allameha A, Mostafaei A. Tehranolide molecule modulates the immune response, reduce regulatory T cell and inhibits tumor growth in vivo. *Mol Immunol.* 47(7-8):1579-1584, 2010.
122. Noori S, Hassan Z, Taghikhani M, Rezaei B, Habibi Z. Dihydroartemisinin can inhibit calmodulin, calmodulin-dependent phosphodiesterase activity and stimulate cellular immune responses. *Int Immunopharmacol.* 10, 213-217 (2010).
123. Noori S, Taghikhani M, Hassan ZM, Allameha A, Mostafaei A. Tehranolide molecule modulates the immune response, reduce regulatory T cell and inhibits tumor growth in vivo. *Mol Immunol.* 2010 Feb 5. [Epub ahead of print]
124. Oh S, Jeong IH, Shin WS, Lee S. Growth inhibition activity of thioacetal artemisinin derivatives against human umbilical vein endothelial cells. *Bioorganic & Medicinal Chemistry Letters* **13**, 3665-3668 (2003).
125. Oh S, Jeong IH, Ahn CM, Shin WS, Lee S. Synthesis and antiangiogenic activity of thioacetal artemisinin derivatives. *Bioorg Med Chem.* **12**, 3783-3790 (2004).
126. Oh S, Shin WS, Ham J, Lee S. Acid-catalyzed synthesis of 10-substituted triazolyl artemisinins and their growth inhibitory activity against various cancer cells. *Bioorg Med Chem Lett.* **20(14)**, 4112-4115 (2010)
127. Oh, S., Kim, B.J., Singh, N.P., Lai, H. & Sasaki, T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. *Cancer Letters* **274**, 33-39 (2009).
128. Opsenica, D., Kyle, D.E., Milhous, W.K. & Solaja, B.A. Antimalarial, antimycobacterial and antiproliferative activity of phenyl substituted mixed tetraoxanes. *Journal of the Serbian Chemical Society* **68**, 291-302 (2003).
129. Opsenica, D. et al. Cholic Acid Derivatives as 1,2,4,5-tetraoxane carriers: structure and antimalarial and antiproliferative activity. *Journal of Medicinal Chemistry* **43**, 3274-3282 (2000).
130. Paik, I.-H. et al. Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. *Journal of Medicinal Chemistry* **49**, 2731-2734 (2006).
131. Payne Anthony, G. Exploiting intracellular iron and iron-rich compounds to effect tumor cell lysis. *Medical Hypotheses* **61**, 206-209 (2003).
132. Posner G. H. et al. New chemical and biological aspects of artemisinin-derived trioxane dimers. *Bioorganic & medicinal chemistry* **10**, 227-232 (2002).
133. Posner, G.H. et al. Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. *Journal of Medicinal Chemistry* **47**, 1299-1301 (2004).
134. Posner, G.H. et al. Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. *Journal of Medicinal Chemistry* **46**, 1060-1065 (2003).
135. Posner, G.H. et al. Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. *Journal of Medicinal Chemistry* **42**, 4275-4280 (1999).
136. Potawale, S.E. et al. Research and medicinal potential of *Artemisia annua*: a review. *Pharmacology Online*, 220-235 (2008).
137. Quetin-Leclercq, J. Potential anticancer and antiparasitic indole alkaloids. *Journal de Pharmacie de Belgique* **49**, 181-192 (1994).
138. Ramacher M, Umansky V, Efferth T. Effect of artesunate on immune cells in ret-transgenic



- mouse melanoma model. *Anticancer Drugs*. 2009 Sep 9. [Epub ahead of print]
139. Rasheed SA, Efferth T, Asangani IA, Allgayer H. First evidence that the anti-malarial drug Artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. *Int J Cancer*. 2010 Mar 15. [Epub ahead of print]
  140. Reungpatthanaphong, P. & Mankhetkorn, S. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. *Biological & Pharmaceutical Bulletin* **25**, 1555-1561 (2002).
  141. Ricci J, Park J, Chung WY, Park KK, Jung M. Concise synthesis and antiangiogenic activity of artemisinin-glycolipid hybrids on chorioallantoic membranes. *Bioorg Med Chem Lett*. 2010 Aug 10. [Epub ahead of print]
  142. Riganti, C., Doublier, S., Viarisio, D., Miraglia, E., Pescarmona, G., Ghigo, D., Bosia, A. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. *British Journal of Pharmacology* 2009 Mar 9. [Epub ahead of print]
  143. Rinner, B. et al. Activity of novel plant extracts against medullary thyroid carcinoma cells. *Anticancer research* **24**, 495-500 (2004).
  144. Rosenthal, A.S. et al. Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. *Journal of Medicinal Chemistry* **52**, 1198-1203 (2009).
  145. Sadava, D., Phillips, T., Lin, C. & Kane, S.E. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. *Cancer Letters* **179**, 151-156 (2002).
  146. Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, Efferth T. Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. *Molecules*. 15(4):2886-2910, 2010.
  147. Sieber, S., Gdynia, G., Roth, W., Bonavida, B. & Efferth, T. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. *Int J Oncol*. **35**, 149-58 (2009).
  148. Singh, N.P. & Lai, H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. *Life Sciences* **70**, 49-56 (2001).
  149. Singh, N.P. & Verma, K.B. Case report of a laryngeal squamous cell carcinoma treated with artesunate. *Arch Oncol* **10**, 279-280 (2002).
  150. Singh, N.P. & Lai, H.C. Artemisinin induces apoptosis in human cancer cells. *Anticancer Research* **24**, 2277-2280 (2004).
  151. Singh, N.P. & Lai, H.C. Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. *Anticancer Research* **25**, 4325-4331 (2005).
  152. Singh N P. & Panwar V.K. Case report of a pituitary macroadenoma treated with artemether. *Integrative Cancer Therapies* **5**, 391-394 (2006).
  153. Sohn, T.A., Bansal, R., Su, G.H., Murphy, K.M. & Kern, S.E. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated. *Carcinogenesis* **23**, 949-957 (2002).
  154. Soomro S, Konkimalla VB, Langenberg T, Mahringer A, Horwedel C, Holenya P, Brand A, Catin C, Fricker G, Dewerchin M, Carmeliet P, Conway EM, Jansen H, Efferth T. Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. *J Cell Mol Med*. 2010 Jul 12. [Epub ahead of print]
  155. Stockwin, L.H., Han, B., Yu, S.X., Hollingshead, M.G., Elsohly, M.A., Gul, W., Slade, D., Galal, A.M. & Newton, D.L. Artemisinin dimer anticancer activity correlates with

- heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. *Int J Cancer*. **125**, 1266-1275 (2009).
156. Sun, W., Han, J., Yang, W., Deng, D. & Yue, X. Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. *Zhongguo Yaoli Xuebao* **13**, 541-543 (1992).
  157. Sundar, S.N., Marconett, C.N., Doan, V.B., Willoughby, J.A., Sr. & Firestone, G.L. Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. *Carcinogenesis* **29**, 2252-2258 (2008).
  158. Tan, X., Plouet, J., Lang, J., Wu, M. & Shen, K. Effects of dihydroartemisinin on proliferation and phosphorylation of mitogen-activated protein kinase in epithelial ovarian cancer cell lines. *Zhonghua Fuchanke Zazhi* **43**, 662-665 (2008).
  159. Utzinger, J., Xiao, S.-H., Tanner, M. & Keiser, J. Artemisinins for schistosomiasis and beyond. *Current Opinion in Investigational Drugs* **8**, 105-116 (2007).
  160. Wang, J., Guo, Y. & Chen, Z. Anti-tumor effect of artemisinin and its derivants. *Yiyao Daobao* **25**, 1042-1044 (2006).
  161. Wang, J. et al. The inhibitory effect of artesunate on human esophageal carcinoma associated with modulation of CDC25A and TGFbeta. *Zhongliu* **27**, 272-276 (2007).
  162. Wang, J. et al. Inhibitory effect of artesunate on human esophageal carcinoma associated with CDC25A modulation. *Di-San Junyi Daxue Xuebao* **29**, 428-431 (2007).
  163. Wang, J. et al. Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. *Pharmacology* **82**, 148-155 (2008).
  164. Wang J et al. Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. *Pharmacology* **80**, 207-218 (2007).
  165. Wang JX et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. *British Journal of Pharmacology* **150**, 652-661 (2007).
  166. Wang JX et al. Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo. *European Journal of Pharmacology* **564**, 211-218 (2007).
  167. Wang, L., Zhang, Y. & Sun, W. Influence of compatibility of artemisinin and mitomycin sera on proliferation of sarcoma A549 in vitro. *Zhongguo Yaoye* **17**, 8-9 (2008).
  168. Wang L, Chen T, Qu J, Wei X. Quantitative analysis of caspase-3 activation by fitting fluorescence emission spectra in living cells. *Micron*. 2009 Jul 23. [Epub ahead of print]
  169. Wang, Q., Wu, L., Li, A., Zhao, Y. & Wang, N. Antitumor effect of artesunate on liver cancer. *Zhongguo Zhongyao Zazhi* **26**, 707-708, 720 (2001).
  170. Wang, Q., Wu, L., Zhao, Y., Zhang, X. & Wang, N. Anticancer effect of artesunate and its mechanism. *Yaoxue Xuebao* **37**, 477-478 (2002).
  171. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, Xue DB, Bai XW, Sun B. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. *Cancer Lett.* **293(1)**, 99-108 (2010).
  172. Wang SJ, Sun B, Pan SH, Chen H, Kong R, Li J, Xue DB, Bai XW, Jiang HC. Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer. *Zhonghua Wai Ke Za Zhi*. **48(7)**, 530-534 (2010).
  173. Wang, W., Zhou, H. & Wang, M. Inhibition of artesunate on angiogenesis of deciduoma and marrow in pseudopregnant rats. *Zhongguo Linchuang Yaoxue Zazhi* **14**, 375-377 (2005).

174. Wang, Y., Zhu, K., Cui, X., Huang, J. & Song, X. Induction of apoptosis of human lung adenocarcinoma A549 cells by artesunate. *Zhonghua Shiyan Waike Zazhi* **24**, 121-122 (2007).
175. Wang, Z., Zhou, H.J., Li, A. & Zhang, J.L. The effect of dihydroartemisinin on TfR and VEGF expression in iron overload human myeloid leukemia K562 cells. *Leukemia Research* 2009 Feb 18. [Epub ahead of print]
176. Wartenberg M et al. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. *Lab Invest* **83**, 1647-1655 (2003).
177. Weifeng T, Feng S, Xiangji L, Changqing S, Zhiquan Q, Huazhong Z, Peining Y, Yong Y, Mengchao W, Xiaoqing J, Wan-Yee L. Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. *Phytomedicine*. 2010 Aug 23. [Epub ahead of print]
178. Willoughby, J.A. et al. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. *Journal of Biological Chemistry* **284**, 2203-2213 (2009).
179. Woerdenbag, H.J. et al. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. *Journal of Natural Products* **56**, 849-856 (1993).
180. Wu, J.M. et al. Synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group. *European Journal of Medicinal Chemistry* **36**, 469-479 (2001).
181. Wu XH et al. Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. *Anticancer Drug* **17**, 839-848 (2006).
182. Wu XL, Zhang WG, Shi XM, An P, Sun WS, Qiao CL, Wang Z. [Effects of artemisinin on proliferation, apoptosis and Caspase-3 expression of rat mesangial cell] *Zhong Yao Cai*. 33(3):407-410, 2010. [Article in Chinese]
183. Wu ZP et al. Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. *Integrative Cancer Therapy* **8**, 88-92 (2009).
184. Xie, B. & Ling, J. Advances in anticancer efficacy of artemisinin and its derivatives. *Guangzhou Zhongyiyao Daxue Xuebao* **22**, 75-77 (2005).
185. Xie W-L, Yang P-H, Zeng X, Cai J-Y. Effect of 4-(12-dihydroartemisininoxy) benzoic acid hydrazide transferrin tagged drug on human breast cancer cells. *Chin J Anal Chem* **37**, 671-675 (2009).
186. Xie WL, Yang PH, Zeng X, Wang H Cai HH, Cai JY. Visual characterization of targeted effect of holo-transferrin-tagged dihydroartemisinin on human breast cancer cells. *Chinese Biology Bulletin* **55**, 2390-2395 (2010)
187. Xu H et al. Anti-malarial agent artesunate inhibits TNF- $\alpha$ -induced production of proinflammatory cytokines via inhibition of NF- $\kappa$ B and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. *Rheumatology* **46**, 920-926 (2007).
188. Yamachika, E., Habte, T. & Oda, D. Artemisinin: An alternative treatment for oral squamous cell carcinoma. *Anticancer Research* **24**, 2153-2160 (2004).
189. Yang, L., Wu, B. & Dai, B. Effect of Qing Hao Su on the frequency of micronucleus of mouse bone marrow polychromatic erythrocytes. *Zhongyao Tongbao* **9**, 132-134 (1984).
190. Yao, L., Xie, H., Jin, Q.-Y., Hu, W.-L. & Chen, L.-J. Analyzing anti-cancer action mechanisms of dihydroartemisinin using gene chip. *Zhongguo Zhong Yao Za Zhi* **33**,

- 1583-1586 (2008).
191. Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A, Hoheisel JD. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. *Biochem Pharmacol.* 78:273-283 (2009)
  192. Yuan, D. & Zhang, C. Effect of artesunate on prostate cancer cell line PC-3. *Zhongguo Yiyuan Yaoxue Zazhi* **27**, 1049-1051 (2007).
  193. Zhang, C.-C., Zhang, X.-P., Yuan, D. & Xiong, Z.-G. Induction of apoptosis in human prostate cancer PC-3 cells by artesunate. *Guangdong Yixue* **29**, 374-376 (2008).
  194. Zhang S, Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. *PLoS One.* 4(10):e7472 (2009).
  195. Zhang S, Chen H, Gerhard GS Heme synthesis increases artemisinin-induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. *Chem Biol Interact.* 186, 30-35 (2010).
  196. Zhang, X., Yang, X. & Pan, Q. Antitumor effect and apoptosis induction in human liver cancer cell line (BEL-7402) by sodium artesunate. *Zhongcaoyao* **29**, 467-469 (1998).
  197. Zhang, Z. Progress in anti-angiogenesis drugs to lung cancer. *Zhongguo Feiai Zazhi* **9**, 96-99 (2006).
  198. Zhang, Z.-Y. et al. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial. *Zhongxiyi Jiehe Xuebao* **6**, 134-138 (2008).
  199. Zhao, X.-B., Liu, M.-X., Wu, K.-N. & Xing, T.-Y. Effects of artesunate and its mechanism on MCF-7 cells. *Zhongliu Fangzhi Yanjiu* **33**, 745-747 (2006).
  200. Zheng, J.-S., Wang, M.-H., Huang, M., Luo, Y.-P. & Mi, C. Artesunate suppresses human endometrial carcinoma RL95-2 cell proliferation by inducing cell apoptosis. *Nanfang Yike Daxue Xuebao* **28**, 2221-2223 (2008).
  201. Zheng GQ. Cytotoxic terpenoids and flavonoids from *Artemisia annua*. *Planta Med* **60**, 54-57 (1994).
  202. Zhou, G.-B., Chen, S.-J., Wang, Z.-Y. & Chen, Z. Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. *Cell Research* **17**, 274-276 (2007).
  203. Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. *Vascul Pharmacol* **47**, 131-138 (2007).
  204. Zhou HJ, Wang Z, Li A. Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression. *Anticancer Drugs.* 19(3):247-255 (2008).
  205. Zhou HJ, Zhang JL, Li A, Wang Z, Lou XE. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. *Cancer Chemother Pharmacol.* **66**, 21-29 (2010).
  206. Zhao, M., Xue, D.B., Zheng, B., Zhang, W.H., Pan, S.H. & Sun, B. Induction of apoptosis by artemisinin relieving the severity of inflammation in caerulein-induced acute pancreatitis. *World J Gastroenterol* **13**, 5612-5617 (2007).

## Artemisinin Pharmacology and Pharmacokinetics

1. Dhingra V, Rao KV, Narasu NL: Current status of artemisinin and its derivatives as antimalarial drugs. *Life Sci* 66:279-300, 2000.
2. Li Q, Si Y, Xie L, Zhang J, Weina P. Severe embryoletality of artesunate related to pharmacokinetics following intravenous and intramuscular doses in pregnant rats. *Birth Defects Res B Dev Reprod Toxicol.* 86(5):385-393, 2009.
3. Li Y, Wu YL: An over four millennium story behind qinghaosu (artemisinin--a fantastic antimalarial drug from a traditional chinese herb). *Curr Med Chem* 10(21):2197-2230, 2003.
4. Medhi B, Patyar S, Rao RS, Byrav Ds P, Prakash A. Pharmacokinetic and Toxicological Profile of Artemisinin Compounds: An Update. *Pharmacology* 84(6):323-332, 2009.
5. Navaratnam V, Mansor SM, Sit NW, et al: Pharmacokinetics of artemisinin-type compounds. *Clin Pharmacokinet* 39:255-270, 2000.